TRANSFORMING ENCAPSULATION OF NUCLEIC ACIDS

DECENTRALISATION

EFFICIENCY

FLEXIBILITY

SUSTAINABILITY

Personalized medicine produced in minutes
Until now, manufacturing of therapeutic products requiring in-vitro or in-vivo transfection using genetic biomolecules has been very expensive and time-consuming. Emerging technologies show us how to do things never done before. They are largely unrealised and require transformation into solutions to maximize the use and benefit.
NANOme is our solution to lower these barriers and make personalized medicine more accessible.
NANOme is a disruptive technology providing a closed, disposable device for individualized patient manufacturing of encapsulated transfection material.
NANOme will be the first fully GMP-compliant lipid nanoparticle-encapsulation device enabling both centralized and de-centralized encapsulation.
NANOme is rapidly adaptable to clinical use of personalized medicines such therapeutic cancer vaccines and as an adjunct to platforms for CAR-T.

YouTube

By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

A new level of vaccine manufacturing
Fully automated aseptic device for next generation LNP-based genetic medicines encapsulation under GMP PAT enabling approach for process control and product release.
Flexible volume, fast and seamless scale-up of LNP from preclinical testing through to supply of GMP clinical trial material and ultimately commercial manufacturing, Robust, fast and cost-efficient.
A single NANOus system can produce 6-8 million vaccine doses per day, enabling exceptionally fast delivery of products to the market with a compact technical setup.
NANOus can be used for a broad range of delivery systems including lipid nanoparticles, liposomes and micelles. Integrated in-process controls enable time savings while retaining exceptionally high product quality. Set-up processes are accelerated, and validation only takes a few weeks instead of months.
Current processes of manufacturing vaccines can be taken to a new level by using our innovative aseptic cGMP technology.

SCALABILITY

EFFICIENCY

FLEXIBILITY

AGILITY

Discover LEON’s solutions of state-of-the-art nanoparticle production processes, and technology for scale-up and commercial manufacturing.

One reactor for all your needs
NANOnow is LEONs patented jet impinging technology based on a classic bottom-up approach for the synthesis of nanoparticles or microparticles. This results in the continuous precipitation of particle sizes between 10 nm and to 70 µm with consistent reproducibility.
Our technology can be used for nucleic acid payloads for cell transfection as well as improving solubility of poorly water-soluble APIs.
LEON offers a broad range of particle types to meet a variety of requirements, whenever there is a need to re-produce easily and with scale, including:

SURFACE-STABILISED CTYSTALLINE NANOPARTICLES

POLYMERIC NANOPARTICLES

LIPOSOMES

SOLID-LIPID NANOPARTICLES

NANOEMULSIONS

MICELLES

YouTube

By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

With NANOsolv we expedite APIs, revitalize forgotten formulations and breathe new life into generics to deliver improved stability, increased solubility and enhanced bioavailability.

Our solution is based on our proprietary NANOnow Technology, a classic bottom-up approach to the synthesis of SMART nanoparticles or microparticles.

Our definition of SMART

Stable crystalline or polymeric particles
Measurable tailored size: 10 nm – 70 um
Achievable easy scale-up: bench to commercial
Relevant for all application forms
Timebound: fast continuous precipitation < 0.1 ms easily integrated into downstream processes

Our development pathway and equipment allow rapid prototype nano formulations and testing in pre-clinical models, with easy scale-up to support clinical and commercial availability. New formulations can be developed faster and the process can be validated easily enabling faster and more efficient clinical development. At LEON, we provide all the services needed to support Drug Product formulation delivery at nano scale, from initial concept through to product approval.

We work collaboratively with our pharmaceutical partners on a contract or co-development basis. The engagement process typically follows key stages.

FOLLOW US ON